This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of interferon beta-1a
MSMED_INTERFERONBETA1A
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
893 |
4. Check minimum number of events
Min. number of events
3
|
893 |
5. Include endpointsNone |
893 |
6. Filter based on genotype QC (FinnGen only) |
893 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of interferon beta-1a
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 893 | 710 | 183 |
| Unadjusted period prevalence (%) | 0.21 | 0.24 | 0.08 |
| Median age at first event (years) | 36.20 | 36.06 | 36.78 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 799
- Matched controls
- 7991
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
32.9
323.0
464
322
109
Kela drug reimbursment
Multiple sclerosis
8591.5
323.0
768
30
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
5037.0
323.0
762
25
L03AB07
ATC
interferon beta-1a; parenteral
+∞
323.0
799
*
G35
ICD-10 Finland
Multiple sclerosis
+∞
323.0
799
48
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
2186.5
323.0
698
25
L03AX13
ATC
glatiramer acetate; parenteral
336.4
323.0
310
15
H46
ICD-10 Finland
Optic neuritis
137.9
283.0
291
33
N86
ICPC
Multiple sclerosis
314.4
281.4
271
13
164
Kela drug reimbursment
Fingolimod
550.4
217.9
207
5
N04BB01
ATC
amantadine; oral
100.4
214.0
230
32
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
112.0
213.1
226
28
L04AA31
ATC
teriflunomide; oral
470.2
191.6
184
5
353
Kela drug reimbursment
Cladribine and fingolimod
553.5
182.9
175
*
L04AX07
ATC
dimethyl fumarate; oral
233.4
181.5
181
10
L04AA27
ATC
fingolimod; oral
442.4
178.0
172
5
N07XX09
ATC
[U] dimethyl fumarate; oral
415.5
169.1
164
5
L03AB08
ATC
interferon beta-1b; parenteral
223.3
129.9
131
7
TAB00
NOMESCO Finland
Lumbar puncture
15.3
122.8
215
188
M03BX01
ATC
baclofen; systemic
43.3
119.9
149
42
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
27.1
107.9
151
68
XA800
NOMESCO Finland
Neuropsychological investigation
14.8
93.7
164
137
XCK00
NOMESCO Finland
Perimetry
12.9
92.4
173
168
G04BD09
ATC
trospium; oral
35.6
91.8
119
39
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
35.5
83.3
108
35
G04BD12
ATC
mirabegron; oral
9.7
80.5
176
227
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
812.3
76.6
74
*
2AB04
NOMESCO Finland
NA
92.6
75.6
83
10
XKD06
NOMESCO Finland
Physiologic investigation of micturition
22.0
73.4
109
57
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.2
70.6
259
674
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
7.2
66.2
176
303
ZX120
NOMESCO Finland
Intravenous
7.0
65.7
177
310
XKD00
NOMESCO Finland
Uroflowmetry
7.8
65.7
164
257
G04BD04
ATC
oxybutynin; oral, transdermal
13.4
64.9
117
101
R20.2
ICD-10 Finland
Paraesthesia of skin
7.0
63.7
171
297
N06BA07
ATC
modafinil; oral
65.7
62.7
72
12
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
61.2
58
*
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
102.6
60.9
66
7
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.0
54.2
165
334
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
283.9
52.8
53
*
G04BD07
ATC
tolterodine; oral
11.7
49.8
95
91
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
18.8
49.6
77
45
H02AB04
ATC
methylprednisolone; systemic
4.2
48.9
216
646
UKC02
NOMESCO Finland
Cystoscopy
5.3
47.1
158
355
XKC03
NOMESCO Finland
Water cystometry
13.7
47.1
83
67
N03AX12
ATC
gabapentin; oral
4.0
45.8
213
663
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
10.0
44.9
93
104
G04BD08
ATC
solifenacin; oral
8.9
44.3
98
123
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
43.1
41
*
N03AE01
ATC
clonazepam; systemic
6.1
42.3
123
231
4AA23
NOMESCO Finland
NA
155.0
42.2
44
*
R1250
NOMESCO Finland
Evaluation of functional capability
12.2
41.1
76
68
H53.2
ICD-10 Finland
Diplopia
12.1
39.2
73
66
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.9
38.5
114
218
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
27.7
38.1
52
20
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.5
34.9
110
226
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.0
34.5
120
275
TKC22
NOMESCO Finland
Catheterisation instruction
15.9
33.6
55
37
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.7
30.2
59
59
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
86.0
30.0
33
*
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
29.3
28
*
N05CF01
ATC
zopiclone; oral
2.6
29.3
281
1388
R4150
NOMESCO Finland
Neuropsychological rehabilitation
17.4
29.2
46
28
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
9.3
28.5
60
69
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.9
28.4
73
115
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
18.9
28.2
43
24
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
7.3
28.0
69
102
R35
ICD-10 Finland
Polyuria
6.1
27.6
78
139
N03AX16
ATC
pregabalin; oral
2.6
25.6
231
1088
R33
ICD-10 Finland
Retention of urine
6.4
24.8
67
113
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.2
23.9
96
252
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
8.0
23.5
54
72
G04BD11
ATC
fesoterodine; oral
9.2
22.9
48
55
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
12.3
22.7
41
35
J01EA01
ATC
trimethoprim; systemic
2.3
22.4
254
1332
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.7
22.1
78
180
L04AA40
ATC
cladribine; oral
+∞
22.0
21
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.9
21.6
93
260
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
12.8
21.5
38
31
R4110
NOMESCO Finland
Physiotherapy
2.4
21.2
228
1160
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.9
20.9
48
64
R4120
NOMESCO Finland
Occupational therapy
3.9
20.4
87
241
SPAT1229
SPAT
Assessment of need for aid
4.5
19.8
72
171
C10AC01
ATC
colestyramine; oral
6.0
18.9
53
94
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
19.3
18.7
28
15
N29
ICPC
Neurological sympt/complt other
11.0
18.6
35
33
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
45.1
18.3
22
5
TKC20
NOMESCO Finland
Catheterisation of bladder
4.7
18.0
62
140
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
17.7
133
552
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
11.9
17.6
32
28
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
17.4
217
1167
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.8
17.3
123
494
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.8
17.2
76
217
A02BC02
ATC
pantoprazole; systemic
1.9
17.1
498
3709
RF120
NOMESCO Finland
NA
10.4
17.0
33
33
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
22.4
16.9
24
11
J01CA08
ATC
pivmecillinam; oral
1.9
16.7
400
2766
L28
ICPC
Limited function/disability (L)
2.9
16.5
107
405
N03AF01
ATC
carbamazepine; oral, rectal
4.2
16.5
63
158
G50.0
ICD-10 Finland
Trigeminal neuralgia
7.5
16.2
38
53
H02AB07
ATC
prednisone; oral
2.5
16.0
135
596
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
16.1
15.8
25
16
RF410
NOMESCO Finland
NA
12.0
15.6
28
24
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
86.8
15.6
17
*
RF420
NOMESCO Finland
NA
9.7
15.5
31
33
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
163.0
15.5
16
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.6
15.5
45
84
N06AA09
ATC
amitriptyline; systemic
3.0
15.4
96
352
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.3
15.2
57
140
N30.0
ICD-10 Finland
Acute cystitis
2.5
15.0
127
562
L01BB04
ATC
cladribine; systemic
+∞
14.6
14
*
359
Kela drug reimbursment
Mirabegroni
81.6
14.6
16
*
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
11.1
14.6
27
25
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
11.1
14.6
27
25
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.2
14.3
77
257
H53.1
ICD-10 Finland
Subjective visual disturbances
3.3
13.9
72
234
SPAT1231
SPAT
Assessment of adjustments needed in living environment
11.7
13.9
25
22
G04CA02
ATC
tamsulosin; oral
3.1
13.8
78
268
3419X
ICD-9 Finland
Other demyelinating diseases of central nervous system, Demyelinating disease of central nervous system, unspecified
142.3
13.5
14
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
26.2
13.4
18
7
XF400
NOMESCO Finland
ECG with 12 standard connections
2.5
13.3
108
464
XKD03
NOMESCO Finland
Urethral pressure profilometry
6.5
13.3
34
54
N06AB04
ATC
citalopram; systemic
2.0
13.2
199
1140
N06AX16
ATC
venlafaxine; oral
2.1
13.1
161
847
Z50.1
ICD-10 Finland
Other physical therapy
3.7
13.0
58
167
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
23.0
12.9
18
8
A06AD11
ATC
lactulose; oral
2.8
12.5
85
331
34099
ICD-8 Finland
Multiple sclerosis
132.0
12.5
13
*
N99
ICPC
Neurological disease other
8.9
12.1
25
29
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
21.7
12.0
17
8
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
11.9
154
825
R42
ICD-10 Finland
Dizziness and giddiness
2.1
11.7
147
780
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
11.6
97
423
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
11.5
11
*
M03BX02
ATC
tizanidine; oral
1.7
11.5
560
4598
SPAT1216
SPAT
Assessment of functional ability
2.5
11.4
89
375
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
5.6
11.3
32
59
N04BC05
ATC
pramipexole; oral
3.1
11.0
60
203
H04.10
ICD-10 Finland
Dry eye syndrome
2.5
10.9
88
377
N03AF02
ATC
oxcarbazepine; oral
4.1
10.7
41
104
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
111.4
10.4
11
*
N28
ICPC
Limited function/disability (N)
7.9
10.4
23
30
N04BD01
ATC
selegiline; oral
14.8
10.0
16
11
R03CA02
ATC
ephedrine; oral
40.6
10.0
12
*
G04BDXX
ATC
NA
40.6
10.0
12
*
A06AC01
ATC
ispaghula (psylla seeds); oral
1.9
9.9
166
977
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
6.1
9.9
26
44
H47.2
ICD-10 Finland
Optic atrophy
20.3
9.8
14
7
XCK10
NOMESCO Finland
Photography of fundus of eye
2.7
9.7
65
251
G04BD10
ATC
darifenacin; oral
17.8
9.4
14
8
RS221
NOMESCO Finland
NA
5.8
9.3
25
44
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.3
9.1
44
137
G82.2
ICD-10 Finland
Paraplegia, unspecified
15.8
9.1
14
9
L04AX01
ATC
azathioprine; systemic
3.0
9.0
51
175
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
9.0
247
1691
R32
ICD-10 Finland
Unspecified urinary incontinence
5.3
9.0
26
50
G04CA01
ATC
alfuzosin; oral
3.1
9.0
47
156
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.8
9.0
183
1148
G51.0
ICD-10 Finland
Bell palsy
4.7
8.9
29
64
U29
ICPC
Urinary symptom/complaint other
5.0
8.7
27
56
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
7.8
8.7
19
25
U02
ICPC
Urinary frequency/urgency
2.1
8.6
101
515
M01AE01
ATC
ibuprofen; systemic, rectal
2.2
8.5
748
6936
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
20.3
8.5
12
6
RF432
NOMESCO Finland
NA
+∞
8.3
8
*
R15
ICD-10 Finland
Faecal incontinence
5.6
8.3
23
42
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.6
8.3
61
250
U05
ICPC
Urination problems other
3.8
8.2
33
89
A28
ICPC
Limited function/disability NOS
2.5
8.2
63
265
Z43.5
ICD-10 Finland
Attention to cystostomy
33.7
8.1
10
*
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
33.7
8.1
10
*
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
33.7
8.1
10
*
SPAT1325
SPAT
Vaccination
1.7
8.0
199
1317
U04
ICPC
Incontinence urine
3.5
8.0
35
102
RS340
NOMESCO Finland
NA
13.2
7.9
13
10
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
13.2
7.9
13
10
N02BE01
ATC
paracetamol; systemic, rectal
1.7
7.8
652
5800
U13
ICPC
Bladder symptom/complaint other
4.2
7.7
28
69
R20.0
ICD-10 Finland
Anaesthesia of skin
9.0
7.6
15
17
RF210
NOMESCO Finland
NA
3.6
7.5
32
91
KA1AE
NOMESCO Finland
Kidney ultrasound examination
4.9
7.5
23
48
H57.1
ICD-10 Finland
Ocular pain
3.0
7.5
40
136
RF312
NOMESCO Finland
NA
80.8
7.4
8
*
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
80.8
7.4
8
*
F02.89
ICD-10 Finland
Dementia in another specified disease that is classified elsewhere without information of additional symptoms
80.8
7.4
8
*
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
11.0
7.3
13
12
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
9.5
7.3
14
15
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
15.9
7.2
11
7
R30.0
ICD-10 Finland
Dysuria
3.3
7.2
35
111
K59.0
ICD-10 Finland
Constipation
3.3
7.2
34
106
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.1
7.1
81
411
H57.9
ICD-10 Finland
Disorder of eye and adnexa, unspecified
6.7
7.1
17
26
U71
ICPC
Cystitis/urinary infection other
2.5
7.0
53
222
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
6.9
162
1051
U07
ICPC
Urine symptom/complaint other
2.7
6.9
45
174
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.5
6.8
297
2246
A02BA02
ATC
ranitidine; systemic
1.8
6.8
117
691
SFA20
NOMESCO Finland
Filling on two surfaces of tooth
1.5
6.7
492
4148
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.5
6.7
257
1886
K59.09
ICD-10 Finland
Constipation, unspecified
2.9
6.5
37
130
R19.5
ICD-10 Finland
Other faecal abnormalities
5.8
6.5
17
30
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
14.4
6.4
10
7
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
8.2
6.3
13
16
WX320
NOMESCO Finland
Spinalanesthesy
0.5
6.3
53
985
G04BD01
ATC
emepronium; systemic
9.4
6.3
12
13
WW400
NOMESCO Finland
Plasmaferesis
18.2
6.3
9
5
3773A
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[PAPILLITIS OPTICA]
+∞
6.3
6
*
34109
ICD-8 Finland
Other demyelinating diseases of central nervous system, Unspecified
+∞
6.3
6
*
TJG30
NOMESCO Finland
Anal sphincter training
+∞
6.3
6
*
G37.0
ICD-10 Finland
Diffuse sclerosis
+∞
6.3
6
*
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.5
6.2
257
1914
4AA36
NOMESCO Finland
NA
26.9
6.2
8
*
U01
ICPC
Dysuria/painful urination
2.2
6.2
59
278
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.5
6.2
44
179
N06AX21
ATC
duloxetine; oral
1.8
6.2
100
580
R13
ICD-10 Finland
Dysphagia
2.5
6.0
43
175
J01MA02
ATC
ciprofloxacin; systemic
1.5
6.0
252
1880
SPAT1262
SPAT
Handing over of treatment supplies
1.8
6.0
97
562
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
122
10
141.15
243.54
2.8
1.4
—
—
—
0
0
164
131
15.11
173.09
1.2
1.1
—
—
—
0
0
724
3583
6.39
121.18
14.2
5.8
26.3
29.3
%
12.05
714
3387
719
3548
6.27
120.45
13.8
5.6
58.5
56.7
%
4.22
710
3362
90
45
22.13
119.16
2.7
2.1
16.8
11.4
%
1.94
43
24
82
48
18.71
100.88
4.3
2.4
0.2
0.2
e9/l
2.04
71
42
83
50
18.20
100.71
4.3
2.5
404.0
536.6
e6/l
0.93
71
43
753
4195
6.07
99.45
15.1
8.8
3.4
4.0
e9/l
21.47
727
3707
152
247
7.21
92.55
1.9
1.6
420.1
0.0
iu/ml
—
5
36
71
45
17.05
83.78
2.7
2.1
—
—
—
0
0
341
1203
3.97
82.26
4.4
2.2
4.6
7.9
e6/l
3.59
316
1058
50
15
35.25
78.70
1.3
1.1
—
—
—
0
0
583
3007
3.70
77.04
2.4
2.3
98.3
74.9
nmol/l
44.97
554
2816
388
1601
3.52
72.11
5.3
2.6
0.1
0.3
e6/l
3.79
330
1176
63
63
10.68
56.34
4.7
2.4
920.0
683.5
e6/l
1.30
38
23
53
44
12.74
53.49
1.2
1.1
1388.4
1716.3
miu/ml
0.90
53
44
250
941
3.30
51.35
4.8
2.3
1.0
1.0
e6/l
0.01
152
501
236
871
3.32
49.93
4.9
2.4
5.2
3.6
e6/l
0.71
138
432
683
4596
3.07
45.41
9.5
3.5
30.0
693.4
e6/l
—
9
50
39
25
16.27
45.39
5.5
2.8
—
—
—
0
0
71
146
5.20
33.10
4.6
4.4
61.1
57.7
%
1.26
71
146
70
143
5.23
32.88
4.6
4.0
3.4
4.3
e9/l
3.72
70
143
528
3581
2.16
27.20
7.1
2.9
0.0
0.0
estimate
0.00
121
668
532
3629
2.15
26.86
7.1
2.9
0.0
0.0
estimate
1.06
124
657
528
3593
2.15
26.80
9.6
4.1
0.0
0.0
estimate
0.38
122
685
37
49
7.83
26.49
3.4
2.7
47.1
46.1
%
0.08
17
12
29
6
49.85
24.40
1.2
1.2
—
—
—
0
0
22
19
11.85
21.42
2.0
2.2
—
—
—
0
0
477
3397
1.87
18.36
4.6
5.8
9.4
10.1
umol/l
1.56
460
3205
620
7236
0.53
15.68
3.0
3.4
1.2
1.3
mmol/l
0.28
571
6901
654
7510
0.52
15.67
3.3
3.7
1.5
1.5
mmol/l
0.43
596
7178
661
7534
0.53
14.49
3.3
3.7
4.9
4.9
mmol/l
0.08
616
7230
876
8072
5.48
13.68
17.2
8.7
27.1
26.2
u/l
1.08
868
7892
673
7594
0.54
13.20
3.5
3.9
2.9
2.9
mmol/l
0.19
616
7243
73
287
2.68
12.96
1.4
1.3
—
—
—
0
0
93
432
2.29
11.55
2.8
1.6
—
—
—
0
0
757
6642
1.92
11.06
22.3
12.7
13.3
13.5
%
3.51
750
6529
106
572
1.97
8.90
2.4
2.1
5422.8
4111.5
u/l
0.11
33
240
648
5621
1.56
7.84
4.7
2.9
42.2
38.7
u/l
0.55
629
5407
368
2853
1.49
7.63
8.4
2.9
—
—
—
0
0
817
7601
1.88
6.55
12.4
10.5
19.1
19.2
mg/l
0.03
593
5798
609
5299
1.47
6.51
5.3
6.9
72.4
73.7
u/l
0.49
575
5025
23
70
3.35
6.45
1.0
1.1
—
—
—
0
0
332
2608
1.43
6.07
3.6
3.2
27.7
29.5
u/l
0.68
320
2510
51
243
2.17
6.01
1.5
1.6
—
—
—
0
0
244
1843
1.45
5.40
9.5
3.2
0.0
0.0
estimate
1.08
125
675
23
79
2.96
5.33
2.8
2.8
0.5
1.3
%
1.67
23
60
5
0
+∞
5.21
1.4
0.0
—
—
—
0
0
293
2303
1.41
5.16
1.7
1.7
98.2
98.8
pmol/l
0.08
149
1254
24
91
2.68
4.68
1.0
1.1
—
—
—
0
0
44
227
1.99
4.28
1.3
1.4
26.6
24.5
u/l
0.16
35
189
599
6554
0.74
4.21
3.6
4.3
36.9
38.1
mmol/mol
3.86
553
6256
101
1474
0.65
4.17
1.2
1.3
1.8
10.1
u/ml
5.03
42
643
786
7396
1.52
4.06
11.3
10.5
139.9
139.6
mmol/l
2.69
773
7226
787
7419
1.51
3.90
11.3
10.6
3.9
3.9
mmol/l
1.40
768
7229
35
172
2.08
3.90
1.4
1.7
455.5
139.4
e6/l
0.56
28
142
35
172
2.08
3.90
1.3
1.6
11.7
10.8
e6/l
0.05
28
136
753
7040
1.44
3.87
11.2
8.8
96.4
91.2
ml/min/173m2
11.28
641
5753
121
850
1.49
3.82
1.7
1.8
—
—
—
0
0
24
103
2.37
3.69
1.0
1.1
—
—
—
0
0
427
3723
1.28
3.33
3.8
4.3
6.0
6.4
mmol/l
5.22
395
3421
10
28
3.60
3.20
1.5
2.8
—
—
—
0
0
664
7078
0.76
3.14
3.2
3.6
5.6
5.7
mmol/l
1.64
608
6686
752
7093
1.38
3.10
5.4
4.8
1.7
2.1
mu/l
1.03
716
6759
216
1748
1.31
2.93
1.9
2.1
128.7
153.5
u/l
0.45
208
1665
75
1075
0.67
2.82
1.5
1.6
—
—
—
0
0
158
1230
1.35
2.80
1.4
1.4
21.3
20.9
nmol/l
0.12
136
1107
300
2549
1.27
2.76
4.1
4.7
37.2
37.0
g/l
0.40
274
2409
82
571
1.48
2.74
1.7
1.7
—
—
—
0
0
82
582
1.45
2.50
1.7
1.7
—
—
—
0
0
186
1505
1.30
2.50
8.1
3.1
1.0
1.0
kg/l
0.20
25
190
119
1539
0.74
2.46
1.3
1.3
10.9
26.7
iu/ml
7.12
30
502
31
518
0.58
2.31
1.2
1.5
—
—
—
0
0
103
781
1.36
2.18
2.2
2.5
4.3
6.0
umol/l
1.88
87
663
606
6427
0.82
1.98
3.6
3.7
—
—
—
0
0
20
105
1.93
1.96
1.4
1.3
—
—
—
0
0
20
105
1.93
1.96
1.4
1.3
—
—
—
0
0
10
39
2.58
1.92
1.0
1.1
—
—
—
0
0
144
1750
0.79
1.86
4.6
3.1
8.1
8.1
mmol/l
0.04
132
1538
34
523
0.64
1.84
2.1
2.2
80.9
77.3
ml/min/173m2
0.18
12
206
27
435
0.61
1.79
1.5
1.7
4.5
3.4
mg/l
0.27
16
296
106
838
1.30
1.72
1.4
1.6
1095.5
1189.1
nmol/l
0.28
82
667
24
393
0.60
1.71
1.7
1.9
—
—
—
0
0
576
5398
1.19
1.70
2.8
3.7
9.1
9.3
mm/h
0.26
543
5106
18
317
0.56
1.68
1.7
1.7
—
—
—
0
0
16
83
1.94
1.65
1.1
1.2
—
—
—
0
0
23
137
1.70
1.56
1.6
6.8
—
223.5
—
0
20
13
64
2.05
1.54
1.2
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
44
2.29
1.53
1.0
1.1
—
—
—
0
0
124
1019
1.25
1.49
2.9
3.1
717.5
287.9
ng/l
0.40
68
570
304
3369
0.85
1.48
3.5
3.9
—
—
—
0
0
80
628
1.30
1.40
2.3
2.3
51.2
38.3
u/l
0.24
61
525
14
74
1.91
1.39
1.2
1.4
239.7
407.8
pmol/l
—
9
55
11
54
2.05
1.33
1.0
1.1
—
—
—
0
0
19
113
1.70
1.32
1.5
3.1
—
2577.1
—
0
11
59
767
0.75
1.31
1.3
1.5
—
—
—
0
0
9
43
2.10
1.30
1.2
1.3
—
—
—
0
0
57
740
0.75
1.26
1.9
2.1
315.2
372.7
nmol/l
1.67
52
693
6
25
2.41
1.24
1.0
1.1
—
—
—
0
0
6
25
2.41
1.24
1.0
1.1
88.2
96.9
%
—
6
25
132
1545
0.83
1.20
5.6
3.9
6.5
9.6
mg/mmol
0.64
92
993
6
26
2.32
1.19
1.3
1.5
—
—
—
0
0
6
26
2.32
1.19
1.3
1.5
—
—
—
0
0
80
977
0.80
1.11
1.6
1.8
—
—
—
0
0
5
21
2.39
1.09
1.0
1.6
—
—
—
0
0
5
21
2.39
1.09
1.0
1.6
—
—
—
0
0
355
3823
0.88
1.07
2.7
2.8
97.8
82.2
ug/l
0.76
331
3634
53
410
1.31
1.07
1.2
1.3
163.2
236.2
miu/ml
0.84
21
210
68
827
0.81
0.93
1.3
1.3
33.1
26.8
iu/l
0.70
59
714
27
372
0.72
0.93
1.4
1.5
—
—
—
0
0
25
348
0.71
0.91
1.5
2.1
4.8
7.2
ug/l
0.49
20
323
9
152
0.59
0.89
1.3
1.5
—
—
—
0
0
149
1679
0.86
0.88
1.7
2.2
1403.3
4633.2
umol/l
1.49
136
1505
232
2120
1.13
0.84
2.8
2.7
76.3
29.0
ng/l
0.55
117
1015
24
171
1.41
0.83
1.3
1.8
2.5
3.0
g/l
2.88
16
145
39
498
0.77
0.82
1.3
1.5
—
—
—
0
0
312
2903
1.11
0.82
5.7
6.2
1.2
1.2
mmol/l
0.22
260
2476
36
463
0.77
0.81
2.9
4.3
4.7
17.7
ug/l
0.68
31
358
56
682
0.81
0.80
5.4
5.3
—
—
—
0
0
8
48
1.67
0.79
1.4
1.1
—
—
—
0
0
14
90
1.56
0.78
1.0
1.6
—
—
—
0
0
33
427
0.76
0.78
1.2
1.4
—
—
—
0
0
41
515
0.79
0.77
1.6
1.6
285.6
304.8
mu/l
0.21
35
461
33
426
0.77
0.77
1.2
1.4
—
—
—
0
0
33
425
0.77
0.76
1.2
1.4
—
—
—
0
0
62
741
0.82
0.75
1.5
1.7
—
—
—
0
0
33
424
0.77
0.74
1.2
1.4
—
—
—
0
0
276
2566
1.11
0.73
4.8
5.5
1.2
1.2
mmol/l
0.20
248
2370
36
456
0.78
0.73
1.1
1.5
—
—
—
0
0
215
1973
1.12
0.72
1.2
1.3
0.8
1.6
u/ml
1.27
52
571
5
25
2.01
0.72
6.8
2.3
—
—
—
0
0
17
117
1.46
0.72
1.4
2.0
—
1600.0
—
0
5
24
178
1.36
0.69
1.3
1.8
—
—
—
0
0
24
178
1.36
0.69
1.3
1.8
6.3
7.3
g/l
4.26
17
150
24
178
1.36
0.69
1.3
1.8
3.5
3.9
g/l
0.73
16
140
18
250
0.71
0.69
1.2
1.2
—
—
—
0
0
13
192
0.67
0.68
1.5
1.3
278.0
325.0
ug/g
—
6
102
5
28
1.79
0.66
1.2
1.4
—
—
—
0
0
5
29
1.73
0.64
1.2
1.4
—
—
—
0
0
20
268
0.74
0.62
1.4
1.5
—
—
—
0
0
38
467
0.81
0.62
1.4
1.5
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
52
437
1.20
0.59
2.6
3.6
1.9
1.9
mmol/l
0.02
42
354
21
157
1.35
0.59
1.7
2.2
191.7
258.2
ug/l
0.23
21
142
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
17
123
1.39
0.58
4.1
3.3
32.8
22.4
mg/l
—
6
80
169
1833
0.90
0.56
1.6
1.6
1.3
1.4
mmol/l
0.69
146
1615
26
203
1.29
0.56
1.7
1.8
—
—
—
0
0
5
89
0.56
0.56
1.2
1.1
—
—
—
0
0
33
266
1.25
0.56
1.3
1.3
—
—
—
0
0
13
182
0.71
0.54
1.8
2.8
1.2
1.3
mg/l
0.46
13
171
19
248
0.76
0.52
1.2
1.2
—
—
—
0
0
6
40
1.50
0.51
1.7
2.9
895.5
720.5
u/ml
—
6
40
41
484
0.84
0.48
1.5
1.5
—
—
—
0
0
67
589
1.15
0.48
3.3
3.6
4.5
4.5
pmol/l
0.22
61
532
28
227
1.24
0.47
1.6
2.6
0.7
0.7
%
0.61
28
221
80
715
1.13
0.45
3.7
3.5
30.5
31.9
%
0.46
62
537
10
69
1.45
0.44
1.2
1.4
—
—
—
0
0
45
522
0.85
0.44
1.7
2.3
0.6
0.6
ug/l
0.52
29
248
51
443
1.16
0.43
2.6
2.9
1.2
1.2
mmol/l
0.09
43
386
101
919
1.11
0.43
2.0
2.3
14.7
14.3
umol/l
0.17
96
856
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
104
1.35
0.43
1.8
4.5
0.3
0.3
u/ml
—
5
49
5
32
1.57
0.42
1.2
1.3
—
—
—
0
0
5
32
1.57
0.42
1.2
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
3.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
1.2
—
0
15
0
15
0.00
0.41
0.0
3.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
21
168
1.26
0.40
1.3
1.8
8.7
10.2
g/l
2.03
16
152
12
160
0.75
0.40
1.1
1.1
—
—
—
0
0
17
133
1.28
0.38
2.2
2.7
—
—
—
0
0
9
66
1.37
0.38
1.9
1.2
—
—
—
0
0
9
66
1.37
0.38
1.9
1.2
—
—
—
0
0
9
67
1.35
0.38
1.9
1.2
—
—
—
0
0
9
67
1.35
0.38
1.9
1.2
—
—
—
0
0
9
67
1.35
0.38
1.9
1.2
—
—
—
0
0
26
311
0.83
0.37
5.3
3.1
5.2
5.2
kpa
0.05
26
294
88
960
0.91
0.36
2.2
2.4
2.4
2.4
mmol/l
0.18
74
845
5
80
0.62
0.35
1.6
1.3
36.4
32.0
nmol/l
—
5
64
9
126
0.71
0.35
1.2
1.2
—
—
—
0
0
29
246
1.18
0.34
2.8
2.0
6.8
5.1
iu/l
0.42
14
95
6
45
1.34
0.33
1.0
1.1
77.9
160.8
iu/ml
—
6
45
6
89
0.67
0.33
1.2
1.2
12.3
11.6
u/l
—
6
76
55
493
1.12
0.32
1.1
1.0
—
—
—
0
0
12
154
0.78
0.32
1.0
1.0
—
0.1
—
0
31
26
221
1.18
0.31
1.9
2.0
—
—
—
0
0
81
746
1.09
0.30
2.0
2.4
24.9
24.2
%
0.17
66
643
7
55
1.27
0.30
1.0
1.2
—
2.4
—
0
5
735
7431
0.94
0.28
19.6
11.3
40.5
40.4
%
0.30
571
6223
8
63
1.27
0.28
1.5
1.2
—
—
—
0
0
14
172
0.81
0.27
1.5
2.2
4.5
4.8
umol/l
—
9
127
63
687
0.91
0.27
2.3
3.1
21.6
21.9
%
0.04
20
213
28
243
1.16
0.27
1.1
1.1
—
—
—
0
0
12
149
0.80
0.26
1.0
1.1
—
—
—
0
0
6
82
0.73
0.24
1.2
1.5
—
—
—
0
0
48
525
0.91
0.23
11.9
11.6
1.0
1.2
inr
—
8
91
17
200
0.85
0.23
5.8
3.1
24.5
24.7
mmol/l
0.10
17
190
149
1558
0.95
0.22
1.9
2.1
2.6
2.8
mg/l
0.46
125
1362
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
1.2
—
0
12
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
167
1737
0.95
0.21
1.5
1.7
0.6
0.8
mg/l
2.65
122
1288
12
145
0.83
0.21
1.1
1.3
—
—
—
0
0
11
89
1.24
0.21
1.2
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
0.1
—
0
9
19
165
1.15
0.19
1.6
1.6
—
—
—
0
0
21
184
1.14
0.19
1.2
1.2
—
—
—
0
0
13
109
1.20
0.18
1.2
1.7
—
—
—
0
0
23
204
1.13
0.18
1.4
1.6
—
—
—
0
0
15
174
0.86
0.18
1.2
1.2
—
—
—
0
0
90
946
0.95
0.17
2.7
3.4
0.8
0.8
mmol/l
1.40
85
899
15
129
1.17
0.17
1.2
1.2
—
—
—
0
0
24
215
1.12
0.16
2.0
2.3
8.7
10.1
mg/l
0.51
24
199
157
1623
0.96
0.16
2.0
2.0
—
—
—
0
0
6
78
0.77
0.15
1.5
1.6
—
—
—
0
0
6
78
0.77
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
6
79
0.76
0.15
1.5
1.6
—
—
—
0
0
55
517
1.07
0.15
6.8
9.7
1.0
1.0
mmol/l
0.02
40
396
18
159
1.13
0.15
1.2
1.7
—
—
—
0
0
110
1057
1.05
0.15
2.1
2.8
599.6
632.6
ng/l
0.06
88
859
24
265
0.90
0.15
1.5
1.4
69.2
103.9
pmol/l
0.39
24
259
28
306
0.91
0.14
1.7
1.9
—
—
—
0
0
213
2081
1.03
0.13
2.1
2.5
53.4
55.2
u/l
0.49
202
1957
36
336
1.07
0.12
1.7
1.5
—
—
—
0
0
79
758
1.05
0.12
1.3
1.2
218.1
155.2
iu/ml
0.44
33
306
12
137
0.87
0.12
1.0
1.3
—
—
—
0
0
11
95
1.16
0.11
3.7
2.1
16.1
16.8
%
—
6
50
26
240
1.09
0.11
7.8
9.9
24.3
24.0
mmol/l
0.20
26
233
18
163
1.11
0.11
1.2
1.6
—
—
—
0
0
33
309
1.07
0.10
2.1
2.6
78.9
88.3
ng/l
0.15
27
268
140
1436
0.97
0.10
1.7
1.9
—
—
—
0
0
200
2040
0.97
0.10
1.5
1.6
—
—
—
0
0
126
1228
1.03
0.09
1.4
1.5
446.4
38649080.9
pmol/l
1.81
114
1110
5
47
1.06
0.09
1.0
1.4
7.2
6.5
u/l
—
5
39
206
2025
1.02
0.08
1.5
1.5
—
—
—
0
0
6
72
0.83
0.07
1.0
1.1
—
—
—
0
0
157
1599
0.98
0.07
1.8
2.0
—
—
—
0
0
30
316
0.95
0.07
1.2
1.3
12.5
11.5
u/l
0.15
24
259
8
94
0.85
0.06
1.6
1.4
—
—
—
0
0
15
162
0.92
0.06
2.6
1.9
—
—
—
0
0
12
131
0.91
0.05
2.3
3.7
4.0
3.7
mmol/l
0.76
12
124
10
90
1.11
0.05
1.1
1.4
—
—
—
0
0
30
287
1.05
0.05
1.4
2.2
—
—
—
0
0
43
416
1.04
0.05
4.1
3.8
77.4
78.3
ng/l
0.02
36
387
18
169
1.07
0.05
1.3
1.1
0.7
2.4
u/ml
—
6
90
11
120
0.92
0.05
1.2
1.4
—
—
—
0
0
22
231
0.95
0.04
1.1
1.3
—
2.7
—
0
27
18
170
1.06
0.04
1.3
1.2
303.1
252.4
u/ml
—
10
108
64
628
1.02
0.03
1.2
1.3
75.9
190.9
u/ml
3.49
57
581
87
859
1.01
0.02
2.7
3.2
1.4
1.4
ug/l
0.12
80
793
10
93
1.08
0.02
1.5
2.0
—
—
—
0
0
207
2081
0.99
0.01
2.5
3.3
2.3
2.3
mmol/l
0.03
183
1899
616
6150
1.01
0.01
4.6
4.2
14.4
14.3
pmol/l
0.41
570
5818
10
96
1.04
0.00
1.3
1.4
—
—
—
0
0
22
222
0.99
0.00
4.2
2.3
3.1
3.5
g/l
0.72
22
211
10
103
0.97
0.00
1.5
1.3
—
—
—
0
0
10
103
0.97
0.00
1.2
1.4
—
—
—
0
0
39
395
0.99
0.00
1.5
1.8
—
—
—
0
0
5
51
0.98
0.00
1.2
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
56
560
1.00
0.00
2.4
2.6
—
—
—
0
0
7
72
0.97
0.00
4.9
3.3
17.0
50.4
u/ml
—
7
72
0
5
0.00
0.00
0.0
1.8
—
3.4
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
0.00
2.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
56
0.89
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.3
—
28.5
—
0
6
6
59
1.02
0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
4.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
9
92
0.98
0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
64
0.94
0.00
2.2
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
7
71
0.99
0.00
1.0
1.1
—
—
—
0
0
5
57
0.88
0.00
1.2
1.7
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_INTERFERONBETA1A – Use of interferon beta-1a
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).